Validus Reports has recently
added a new study titled
World Ophthalmology Drugs Market – Industry Analysis, Trends and Forecasts to2023. This report provides an understanding of how epidemiology trends, new
drug entries and new drug patent expirations will influence market value.
Interested to know more about this report? Click here to request for a sample.
Ophthalmology is a broad therapy area that consists of
almost 100 disorders associated with the eyes and visual system, including such
diseases as glaucoma, age-related macular degeneration (AMD), diabetic macular
edema (DME), diabetic retinopathy (DR) and dry eye syndrome (DES). Many of
these disorders are progressive, and if left untreated can lead to severe
visual impairment or even blindness.
The patents protecting the three most commercially
successful products, all marketed in wet AMD, are expected to expire in the
coming years – Lucentis (ranibizumab) and Avastin (Bevacizumab) in 2018, and
Eylea (aflibercept) in 2020. However, revenue from anticipated new approvals
such as lampalizumab in dry AMD, Fovista (pegpleranib sodium) in wet AMD and brolucizumab
in wet AMD and DME is expected to exceed the revenue lost following the patent
expiry of current market leaders.
There is also significant interest in developing products
for other indications; in 2017, Spark Therapeutics is expected to gain FDA
approval in retinitis pigmentosa and Leber congenital amaurosis for its orphan
drug, Voretigene Neparvovec, which if successful will be the first gene therapy
approved for any genetic disease.
At the same time, a number of small and specialized ophthalmology
companies such as Santen and Aerie are expected to enter the market,
diversifying the landscape, which currently consists primarily of large biotech
companies.
Scope
– The ophthalmology therapeutics market is forecast to reach
$35 billion in 2023. What are the key market segments driving this growth?
– The pipeline contains over 800 products. What molecule
types and molecular targets are in the pipeline? What are the commercial
prospects of promising late-stage products?
– Despite specific drug classes such as angiogenesis
inhibitors dominating the commercial landscape, there is a very high proportion
of novel drug classes in the pipeline. Which drug classes account for the
largest proportion of early-stage development, and how do clinical failure
rates, clinical trial size and clinical trial duration differ by indication and
molecular target?
– Although they are dominant in the market, large biotech
companies are anticipated to lose market share to specialty ophthalmology
companies, which are much more active in the pipeline. Which of the leading
companies will have the highest market share by 2023? Which new companies will
enter the market?
– What licensing and co-development deals have occurred
within this therapy area since 2006?
Interested to know more about this report? Click here to request for a sample.
Reasons to buy
– Understand the current clinical and commercial landscape
through a comprehensive analysis of innovation in the ophthalmology
therapeutics market, in the context of the overall pipeline and current market
landscape. The report also includes analysis of the deals landscape, including
both licensing deals and co-development deals. Key indications covered in
detail include glaucoma, AMD, DME, DR and DES.
– Understand the current treatment landscape, with profiles
of key marketed products and a focus on historical and forecast sales patterns,
and an overview of each drug’s mechanism of action.
– Analyze the ophthalmology therapeutics pipeline through a
comprehensive review, segmented by stage of development, molecule type and
molecular target. This review also provides a detailed look at ophthalmology
therapeutics clinical trials, to provide an insight into the risk associated
with attempting to bring pipeline analgesics to market.
– Predict growth in market size, with in-depth market
forecasting from 2016 to 2023. The forecast will provide an understanding of
how epidemiology trends, new drug entries and new drug patent expirations will
influence market value.
– Identify the key pipeline products, with a particular
focus on those due to be brought to market in the near future, as well as sales
forecasts for these products.
– Identify the leading companies in the market, in terms of
market share and growth. Company analysis determines how dependent the key
companies in the market are on revenue derived from ophthalmology therapeutic
products. In addition, analysis determines the primary factors that will drive
market growth for the disease area’s key companies.
– Assess the licensing and co-development deal landscape for
ophthalmology therapies.
About Validus Reports:
Validus Reports is a market research aggregator bringing you
the most comprehensive research studies, in time and at the best prices.
Contact Us:
In case of additional questions and best prices, write to:
Mr. Trevor Cherian
sales@validusreports.com
Comments
Post a Comment